PCD On The Move 2016: Advances in Primary Ciliary Dyskinesia Research, Diagnosis & Care
PDF Imprimir Correo electrónico

There are no translations available.

Primary ciliary dyskinesia (PCD) is on the Move! 

Join us in beautiful Minneapolis, Minnesota for the third annual 'PCD on the Move' conference, an information-packed two day meeting highlighting exciting advances in PCD diagnosis and treatment. Be part of the journey with PCD experts as we map out next steps to accelerate research in PCD!

Register information available here !


(1) Enable attendees to optimize clinical care of patients with PCD by providing education, access to experts and hands-on learning opportunities for recent advances in PCD to include:

A.    Improved diagnostic capabilities (nasal nitric oxide, reading biopsies, genetic
B.     Evolving gene identification
C.     Novel phenotypic features/overlapping syndromes
D.     Basic science initiatives that inform our understanding of motile cilia disorders

(2) Encourage expansion of existing clinical care and research networks with the goal of accelerating clinical research trials

(3) Identify clinical research opportunities and prioritize research goals

Who Should Attend:

  • Existing PCD clinical centers personnel
  • Representatives from academic centers interested in becoming part of the PCD network
  • Local/regional clinicians/researchers
  • Allied health professionals and scientists with an interest in PCD
Conference Agenda:

PCD On The Move 2016 Agenda

Hotel Accomodations:

For hotel information and to book a room for the event-



SPONSORSHIP OPPORTUNITIES ARE AVAILABLE! PLEASE CONTACT LYNN EHRNE AT Esta dirección electrónica esta protegida contra spambots. Es necesario activar Javascript para visualizarla FOR MORE INFORMATION.

Call for Scientific Abstracts and Case Reports 2016
PDF Imprimir Correo electrónico

There are no translations available.

PCD On The Move: Advances in Primary Ciliary Dyskinesia Research, Diagnosis and Care
September 14-16, 2016
Minneapolis, Minnesota



Scientific Abstracts:

Accepted abstracts will be presented in the form of a poster.
Your scientific abstract must contain:
1.  A descriptive title, list of authors and institutions;
2.  An introduction/rationale to the study;
3.  The methods used;
4.  The results of the study;
5.  Conclusions of the study.

Case Reports:

Accepted case reports will be presented in the form of a poster or a 10-minute oral presentation.
Case reports must contain:
1.  A descriptive title, list of authors and institutions;
2.  An introduction;
3.  A description of the case including a detailed description of how the diagnosis was made;
4.  A discussion of the novelty and importance of the scientific case.

Language: The abstract must be submitted and presented in English.

Prior publication: Abstracts which have already been presented at previous meetings can be submitted provided they offer information pertinent to the study of Primary Ciliary Dyskinesia

Funding source: All abstracts must specify the funding source.

Co-authors: It is required that all authors listed on the abstract have knowledge of the abstract submission.

Disclosure: It is required that the primary author disclose any potential conflicts of interest.

Abstract length: The total word count may not exceed 500 words (title, authors’ information, institutions, tables, images, and spaces between words do not count towards the 500 word count).

Abbreviations: Abbreviations should be spelled out on the first occurrence in the text.

Tables/Images: You may include 1 table or figure.


Five case reports will be selected for oral presentation during a Fellows Case Report session on Thursday, September 15.  If your case report abstract is chosen for an oral presentation, the presenter will receive a scholarship to cover travel, lodging, food and registration costs.


Two poster presentations will be recognized for exceptional merit at the conclusion of the poster session and will receive a $250 cash award.  Awards will be based on both scientific content and poster presentation. 


  • Accepted scientific abstracts will be presented as a poster presentation
  • Accepted case reports will be assigned as either an oral or a poster presentation
  • The person assigned as the presenting author will be expected to present at the conference
  • Authors assigned to a poster presentation will be expected to display illustrative material in the form of a poster
  • Authors assigned to an oral presentation will be expected to prepare and 10-minute presentation with Power Point visual aids.  This will be followed by a 5-minute question and answer period.
  • Oral and poster presentations will take place in the afternoon on Thursday, September 15, 2016. 


Posters will be displayed throughout the conference.  Poster set-up and take-down instructions will be provided on-site.  Posters must be formatted to one of the two following dimensions:

• 48”w x 36”h (122cm w x 91cm h)
• 60”w x 36”h (152cm w x 91 cm h)

Please note: The PCD Foundation will not be responsible for posters left at the end of the meeting on Friday, September 16, 2016.


Abstracts are to be submitted in Microsoft Word Format to the PCD Foundation c/o Lynn Ehrne at Esta dirección electrónica esta protegida contra spambots. Es necesario activar Javascript para visualizarla

Notification of abstract acceptance or rejection will be sent electronically to the presenting author within a few days of the deadline.

The body of the email must contain the following information:

  • Name of presenting author
  • Address, email address and phone number of presenting author
  • Title of abstract


Friday, July 22, 2016
5:00 PM, Eastern Time

PCDF Clinical Centers Network
PDF Imprimir Correo electrónico

There are no translations available.

The PCD Foundation Clinical and Research Centers Network

Ultimately, it is the goal of the PCD Foundation to find a cure for PCD. This will require significant investment in research and, because we are a small patient group, the participation of as many affected individuals as possible. To facilitate participation, we and our international partners are dedicated to creating networks of PCD centers ito serve as focal points for diagnosis, research, treatment and data collection (patient registry). To this end, we are proud to announce the creation of The PCD Clinical Centers Network!

This network builds on th existing Genetic Disorders of Mucociliary Clearance [Research] Consortium (GDMCC). GDMCC sites will continue their role as research centers, as well as serving as referral sites for diagnostic and clinical visits under the new PCD Foundation Clinical Centers Network. With over a decade of experience working as an expert network, GDMCC sites will also provide invaluable mentoring services for newer sites joining the network.


Genetic Disorders of Mucociliary Clearance Research Sites (note: most, but not all of these research sites also see patients for non-research clinical visits):



PCD Clinical Network Full Sites

PCD Clinical Network full sites are sites that have met the mandatory requirements to be recognized as a PCD Clinical Center site, including:

-Submitted an application for review and approval by our Clinical Centers Committee
-Identifying a multi-disciplinary team to care for PCD patients

-Ensured access to complete diagnostic services to include ciliary biopsy and nasal nitric oxide measurements
-Agreed to required training, ongoing education and site auditing visits

PCDF Clinical Centers Affiliate Sites

Affiliate sites have submitted an application to be full sites, but may not have all the required resources in place right now, for instance, may not have resources to invest in expensive diagnostic equipment or may not have all required staffing covered at this time. Affiliate sites work cooperatively with full sites and are first in line to be added as full, accredited sites


Stay tuned for developments on this exciting and growing network!


PCD Patient Event: San Francisco, CA May 14, 2016
PDF Imprimir Correo electrónico

There are no translations available.


The American Thoracic Society Public Advisory Roundtable (ATS-PAR) is proud to present their 10th annual “Meet the Experts” Patient/Family Event at the San Francisco Marriott Marquis Hotel on Saturday, May 14th 2016 from 10:00 a.m. - 2:00 p.m. As an ATS-PAR member organization, the PCD Foundation is delighted to announce that Dr. Carlos Milla (Lucille Packard Children’s Hospital, Stanford) and Dr. Steven Brody (Washington University School of Medicine, St. Louis) will be available to meet with patients during this event.

When: May 14th, 2016 from 10:00 am – 2:00 pm
Where: Marriott Marquis Hotel, San Francisco
Cost: Free and lunch provided, but registration is required

This interactive session will be an opportunity for one-on-one discussion with nationally renowned experts in PCD. Questions are encouraged, just note that individual medical consultations cannot be provided at this event. PCD Foundation board members will also be present and available to meet with patients and provide information about the foundation, as will other patients.

This is a free event for patients and family members with complimentary parking, lunch, and oxygen refills for attendees with portable oxygen needs.

Please RSVP as soon as possible to ensure all attendees will be accommodated! We look forward to seeing you there!

Please RSVP by May 1st to Heidi Bjornson-Pennell, PCDF Board Member:

Email: Esta dirección electrónica esta protegida contra spambots. Es necesario activar Javascript para visualizarla

RSVP must include the first and last name of every person in your group and your city and state. Please provide an email if possible. Thank you!

Please click here for more information!
A 30 gene PCD diagnostic panel is now available
PDF Imprimir Correo electrónico

There are no translations available.

Exciting news from Invitae!

A 30 gene PCD diagnostic panel is now available. It is estimated that this panel will pick up approximately 70% of all PCD genetic defects. 

Pricing for this expanded panel is $1500 for individuals who have insurance to cover genetic testing. For patients without insurance or whose insurance does not cover genetic testing, Invitae is offering an out-of-pocket price of $475. There is also discount contract pricing for institutions and academic centers. Please contact Invitae directly for more information related to pricing. 

This is a seminal event for the PCD community. The availability of affordable, reliable genetic test will change the way PCD is diagnosed and will accelerate efforts to understand this complex disorder. 

For more information on ordering tests or for international inquiries please contact Invitae at  Esta dirección electrónica esta protegida contra spambots. Es necesario activar Javascript para visualizarla .

Página 1 de 4